Matches in SemOpenAlex for { <https://semopenalex.org/work/W4253670191> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W4253670191 endingPage "2546" @default.
- W4253670191 startingPage "2540" @default.
- W4253670191 abstract "We report the results of a randomized multicenter study comparing the efficacy of antithymocyte globulin (ATG) with that of cyclosporin A (CsA) as first-line therapy for severe aplastic anemia (SAA). Patients were randomized to receive ATG and prednisone (PDN) or CsA; hematologic response and toxicity were compared. At 3-month evaluation, patients who had no or minimal response received the alternative therapy to assess the value of a sequential immunosuppressive therapy for treatment of severe aplastic anemia. One hundred nineteen patients were randomized; 25 were excluded, of whom 3 were misdiagnosed and 22 did not follow the cross-over protocol. Ninety-four patients were analyzed; 46 received CsA, and 48 received ATG-PDN. The actuarial survival was 66.7%, with a median follow-up time of 19 months. There was no significant difference in survival between the groups with, at 3 months, an actuarial survival of 88% in the CsA group and 75% in the ATG group (NS); at 12 months, it was 70% in the CsA group and 64% in the ATG group (NS). The percentage of complete and partial response was 11.6% and 16%, respectively, at 3 months, and 31.6% and 30%, respectively, at 12 months (NS). The main prognostic factor was the absolute neutrophil count (ANC) at entry: Patients with ANC less than 0.2 x 10(9)/L had a significantly lower survival as compared with patients with more than 0.2 x 10(9)/L ANC (P = .0001). At 12 months, 62 evaluable patients were alive, with a complete or partial response in 36 patients. Patients who had responded to the first treatment had a better recovery of bone marrow failure than those who had sequential immunosuppression. The main complication was infection, which was more often observed and more often lethal during ATG and PDN therapy. In this study, initial treatment of SAA with either CsA or ATG-PDN followed by cross-over therapy for nonresponders produced comparable response and survival rates." @default.
- W4253670191 created "2022-05-12" @default.
- W4253670191 creator A5017512905 @default.
- W4253670191 creator A5018536511 @default.
- W4253670191 creator A5040756049 @default.
- W4253670191 creator A5041046604 @default.
- W4253670191 creator A5049735878 @default.
- W4253670191 creator A5062839406 @default.
- W4253670191 creator A5064149056 @default.
- W4253670191 creator A5085665866 @default.
- W4253670191 creator A5086955681 @default.
- W4253670191 creator A5088462947 @default.
- W4253670191 date "1992-05-15" @default.
- W4253670191 modified "2023-10-01" @default.
- W4253670191 title "Multicenter randomized study comparing cyclosporine-A alone and antithymocyte globulin with prednisone for treatment of severe aplastic anemia" @default.
- W4253670191 doi "https://doi.org/10.1182/blood.v79.10.2540.bloodjournal79102540" @default.
- W4253670191 hasPublicationYear "1992" @default.
- W4253670191 type Work @default.
- W4253670191 citedByCount "61" @default.
- W4253670191 countsByYear W42536701912012 @default.
- W4253670191 countsByYear W42536701912013 @default.
- W4253670191 countsByYear W42536701912015 @default.
- W4253670191 countsByYear W42536701912016 @default.
- W4253670191 countsByYear W42536701912017 @default.
- W4253670191 countsByYear W42536701912019 @default.
- W4253670191 countsByYear W42536701912020 @default.
- W4253670191 countsByYear W42536701912022 @default.
- W4253670191 crossrefType "journal-article" @default.
- W4253670191 hasAuthorship W4253670191A5017512905 @default.
- W4253670191 hasAuthorship W4253670191A5018536511 @default.
- W4253670191 hasAuthorship W4253670191A5040756049 @default.
- W4253670191 hasAuthorship W4253670191A5041046604 @default.
- W4253670191 hasAuthorship W4253670191A5049735878 @default.
- W4253670191 hasAuthorship W4253670191A5062839406 @default.
- W4253670191 hasAuthorship W4253670191A5064149056 @default.
- W4253670191 hasAuthorship W4253670191A5085665866 @default.
- W4253670191 hasAuthorship W4253670191A5086955681 @default.
- W4253670191 hasAuthorship W4253670191A5088462947 @default.
- W4253670191 hasBestOaLocation W42536701911 @default.
- W4253670191 hasConcept C126322002 @default.
- W4253670191 hasConcept C141071460 @default.
- W4253670191 hasConcept C168563851 @default.
- W4253670191 hasConcept C2775965419 @default.
- W4253670191 hasConcept C2778248108 @default.
- W4253670191 hasConcept C2778720950 @default.
- W4253670191 hasConcept C2780007613 @default.
- W4253670191 hasConcept C2781440808 @default.
- W4253670191 hasConcept C2992435398 @default.
- W4253670191 hasConcept C71924100 @default.
- W4253670191 hasConcept C81358767 @default.
- W4253670191 hasConcept C90924648 @default.
- W4253670191 hasConceptScore W4253670191C126322002 @default.
- W4253670191 hasConceptScore W4253670191C141071460 @default.
- W4253670191 hasConceptScore W4253670191C168563851 @default.
- W4253670191 hasConceptScore W4253670191C2775965419 @default.
- W4253670191 hasConceptScore W4253670191C2778248108 @default.
- W4253670191 hasConceptScore W4253670191C2778720950 @default.
- W4253670191 hasConceptScore W4253670191C2780007613 @default.
- W4253670191 hasConceptScore W4253670191C2781440808 @default.
- W4253670191 hasConceptScore W4253670191C2992435398 @default.
- W4253670191 hasConceptScore W4253670191C71924100 @default.
- W4253670191 hasConceptScore W4253670191C81358767 @default.
- W4253670191 hasConceptScore W4253670191C90924648 @default.
- W4253670191 hasIssue "10" @default.
- W4253670191 hasLocation W42536701911 @default.
- W4253670191 hasOpenAccess W4253670191 @default.
- W4253670191 hasPrimaryLocation W42536701911 @default.
- W4253670191 hasRelatedWork W1511775759 @default.
- W4253670191 hasRelatedWork W2003938723 @default.
- W4253670191 hasRelatedWork W2047967234 @default.
- W4253670191 hasRelatedWork W2051975199 @default.
- W4253670191 hasRelatedWork W2100557404 @default.
- W4253670191 hasRelatedWork W2136055775 @default.
- W4253670191 hasRelatedWork W2422516190 @default.
- W4253670191 hasRelatedWork W2439875401 @default.
- W4253670191 hasRelatedWork W4253670191 @default.
- W4253670191 hasRelatedWork W2336352421 @default.
- W4253670191 hasVolume "79" @default.
- W4253670191 isParatext "false" @default.
- W4253670191 isRetracted "false" @default.
- W4253670191 workType "article" @default.